Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab

As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Immunol Lett
Hoofdauteurs: Salvati, Lorenzo, Occhipinti, Mariaelena, Gori, Leonardo, Ciani, Luca, Mazzoni, Alessio, Maggi, Laura, Capone, Manuela, Parronchi, Paola, Liotta, Francesco, Miele, Vittorio, Annunziato, Francesco, Lavorini, Federico, Cosmi, Lorenzo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: European Federation of Immunological Societies. Published by Elsevier B.V. 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7644186/
https://ncbi.nlm.nih.gov/pubmed/33161002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.imlet.2020.10.009
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items